Habiba Umme, Malik Aafia, Raja Ghazala Kaukab, Memon Muhammad Raza, Nizami Asad Tameezud Din, Ishaq Rafaqat, Ilyas Muhammad, Valadi Hadi, Nawaz Muhammad, Shaiq Pakeeza Arzoo
University Institute of Biochemistry and Biotechnology, Pir Mehr Ali Shah, Arid Agriculture University Rawalpindi, Shamsabad, Rawalpindi 46300, Pakistan.
Department of Psychiatry, Jinnah Hospital Usmani Road, Quaid-i-Azam Campus, Lahore 54550, Pakistan.
Brain Sci. 2023 Feb 26;13(3):407. doi: 10.3390/brainsci13030407.
Schizophrenia patients demonstrate variations in response to different therapies that are currently being used for the treatment of disorders, such as augmentation therapy (ECT or mood stabilizer) and combination therapy (with antipsychotics). These therapies are also used to treat schizophrenia patients in Pakistan; however, patients show poor overall response. Therefore, this study was conducted to investigate the association between the patients' response to treatment and the use of antipsychotic agents, with variability in overall response, within different groups of patients. We conducted a retrospective study that included schizophrenia subjects (N = 200) belonging to different age groups, ethnicities, and regions from different outpatient and inpatient departments in psychiatric institutes located in different cities of Pakistan. These patients were assessed for their response to treatment therapies and categorized into four groups (non-responders (N-R), slow response (S-R), patients with relapse, and completely recovered patients (C-R)) according to their responses. The final analysis included 200 subjects, of which 73.5% were males. Mean age was 34 ± 10 years. Percentage of N-R was 5%, S-R was 42%, patients with relapse were 24%, and C-R was 1.5%. The generalized linear regression model shows a significant association between medication response and age ( = 0.0231), age of onset ( = 0.0086), gender ( = 0.005), and marital status ( = 0.00169). Variability within the medication responses was a result of the treatment regime followed. Antipsychotic agents were significantly associated with the treatment response ( = 0.00258, F = 4.981) of the patients. Significant variation was also observed in the treatment response ( = 0.00128) of the patients that were given augmentation therapy as well as combination therapy. The data suggests proper monitoring of patients' behavior in response to treatment therapies to implement tailored interventions. Despite several genetic studies supporting the heritability of schizophrenia, an insignificant association between characteristic features and family history might have been due to the limited sample size, suggesting collaborative work with massive sample sizes.
精神分裂症患者对目前用于治疗精神障碍的不同疗法(如强化治疗(电休克治疗或心境稳定剂)和联合治疗(与抗精神病药物联用))的反应存在差异。这些疗法也用于治疗巴基斯坦的精神分裂症患者;然而,患者的总体反应较差。因此,本研究旨在调查患者对治疗的反应与抗精神病药物使用之间的关联,以及不同患者群体中总体反应的变异性。我们进行了一项回顾性研究,纳入了来自巴基斯坦不同城市精神病院不同门诊和住院科室、不同年龄组、种族和地区的精神分裂症患者(N = 200)。根据这些患者对治疗疗法的反应对他们进行评估,并分为四组(无反应者(N - R)、反应缓慢者(S - R)、复发患者和完全康复患者(C - R))。最终分析包括200名受试者,其中73.5%为男性。平均年龄为34±10岁。无反应者的比例为5%,反应缓慢者为42%,复发患者为24%,完全康复患者为1.5%。广义线性回归模型显示药物反应与年龄( = 0.0231)、发病年龄( = 0.0086)、性别( = 0.005)和婚姻状况( = 0.00169)之间存在显著关联。药物反应的变异性是所遵循治疗方案的结果。抗精神病药物与患者的治疗反应( = 0.00258,F = 4.981)显著相关。在接受强化治疗和联合治疗的患者的治疗反应( = 0.00128)中也观察到了显著差异。数据表明,应适当监测患者对治疗疗法的反应行为,以实施针对性干预。尽管有几项基因研究支持精神分裂症的遗传性,但特征与家族史之间无显著关联可能是由于样本量有限,这表明需要开展大规模样本量的合作研究。